Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL28322407 | 0.86 | SYK (0.52) | ACHEADORA2AADORA1MAPTALDH1A1 | |
| SCHEMBL7978412 | 0.85 | ALDH1A1 (0.57) | ACHEMAPTMEN1ALDH1A1HPGD | |
| SCHEMBL509835 | 0.85 | ADORA2A (0.52) | ACHEADORA2AADORA1MEN1ALDH1A1 | |
| SCHEMBL5529985 | 0.83 | ADORA2A (0.47) | ACHEADORA2AMAPTMEN1ALDH1A1 | |
| SCHEMBL509836 | 0.83 | CYP11B1 (0.57) | ADORA2AMAPTMEN1ALDH1A1HPGD | |
| SCHEMBL508694 | 0.83 | MAP4K4 (0.54) | ADORA2AADORA1BACE1 | |
| SCHEMBL6634946 | 0.80 | KDM4E (0.51) | ACHEADORA2AADORA1MAPTMEN1 | |
| SCHEMBL11375277 | 0.80 | KDM4E (0.50) | ACHEADORA2AADORA1MAPTMEN1 | |
| SCHEMBL29177933 | 0.80 | ACHE (0.52) | ACHEADORA2AADORA1CYP1A1CYP1B1 | |
| SCHEMBL509600 | 0.79 | ADORA2A (0.53) | ADORA2AADORA1ADORA3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935293-B1 | IRIDIUM COMPLEXES AND THEIR USE IN ELECTRONIC DEVICES, ESPECIALLY ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-08-21 | — | — | EP | disclosed |
| CN-107428692-A | Substituted monoazanaphthalene derivatives and polyazanaphthalene derivatives and use thereof | 巴斯利尔药物国际股份公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20150318498-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150318498-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| WO-2014094962-A2 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-06-26 | — | — | WO | disclosed |
| EP-2423196-A1 | 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150318498-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | ACHE 2257/4885ADORA2A 4811/4885ADORA1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.